For the quarter ending 2025-09-30, BOLD had $283K increase in cash & cash equivalents over the period. -$10,210K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -13,879 | -31,433 |
| Stock-based compensation | 1,303 | 3,490 |
| Depreciation and amortization | 310 | 634 |
| Accretion of investments, net | 577 | 1,508 |
| Non-cash lease expense | 801 | 1,674 |
| Prepaid expenses and other assets | 27 | 210 |
| Accounts payable and accrued liabilities | 1,541 | -884 |
| Operating lease liabilities | 333 | 1,878 |
| Net cash used in operating activities | -10,195 | -26,359 |
| Purchases of investments | 39,507 | 96,285 |
| Maturities of investments | 50,000 | 110,744 |
| Purchases of property and equipment | 15 | 107 |
| Net cash provided by/ (used in) investing activities | 10,478 | 14,352 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 0 | 117 |
| Net cash provided by financing activities | 0 | 117 |
| Net increase/ (decrease) in cash, cash equivalents, and restricted cash | 283 | -11,890 |
| Cash and cash equivalents at beginning of period | 27,147 | - |
| Cash and cash equivalents at end of period | 15,540 | - |
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD)